ScreenerHero

ASMB Assembly Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · assemblybio.com
22.82USD-0.57%Mkt Cap: 464.63M $P/E: 21.94

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap464.63M USD
Enterprise Value133.59M USD
Revenue (TTM)74.84M USD
Gross Profit11.19M USD
Net Income (TTM)-6.12M USD
Revenue/Share4.57 USD
Last Price22.82 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees73
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)21.94
P/E (Forward)-8.62
PEG—
EV/EBITDA-15.38
EV/Revenue1.78
P/S6.03
P/B1.44
EPS (TTM)1.02
EPS (Forward)-2.57
52W Range
21.806% of range39.71
52W High39.71 USD
52W Low21.80 USD
Profitability
Gross Margin14.95%
Oper. Margin-47.44%
EBITDA Margin-11.61%
Profit Margin-8.47%
ROE-2.96%
ROA-2.38%
Growth
Revenue Growth38.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.09M USD
CapEx (TTM)66.00K USD
FCF Margin-37.23%
FCF Yield-6.00%
Net Debt-318.01M USD
Net Debt/EBITDA36.60
Balance Sheet
Debt/Equity0.01
Current Ratio13.99
Quick Ratio13.79
Book Value/Sh15.40 USD
Cash/Share15.73 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateFeb 12, 2024
Analyst Consensus
Rating—
Target (Mean)52.00 USD
Upside (mean)+127.9%
Target Range43.00 USD – 62.00 USD
43.00+127.9% to mean62.00
# Analysts5
Ownership
Shares Out.20.36M
Float9.17M
Insiders27.66%
Institutions69.50%
Short Interest
Short Ratio6.4d
Short % Float13.70%
Short % Out.10.29%
Shares Short2.10M
Short (prev mo.)2.31M
Technical
SMA 5028.74 (-20.6%)
SMA 20028.26 (-19.2%)
Beta1.16
S&P 52W Chg16.45%
Avg Vol (30d)343.96K
Avg Vol (10d)247.57K
Technical Indicators
RSI (14)33.3
MACD-1.9680
MACD Signal-1.7951
MACD Hist.-0.1729
BB Upper31.18 USD
BB Middle25.11 USD
BB Lower19.03 USD
BB Width48.37%
ATR (14)1.338 USD
Vol Ratio (20d)0.76x